Inspire Advisors LLC Acquires 214 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Inspire Advisors LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 10.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,348 shares of the medical research company’s stock after buying an additional 214 shares during the quarter. Inspire Advisors LLC’s holdings in IQVIA were worth $557,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Versant Capital Management Inc grew its position in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $29,000. Finally, Riverview Trust Co bought a new stake in shares of IQVIA in the 1st quarter worth approximately $32,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 1.2 %

IQVIA stock opened at $236.61 on Friday. The firm has a market cap of $43.13 billion, a price-to-earnings ratio of 30.73, a PEG ratio of 2.22 and a beta of 1.49. The stock has a fifty day simple moving average of $239.08 and a two-hundred day simple moving average of $231.26. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.22 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on IQV shares. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. JPMorgan Chase & Co. raised their target price on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. Truist Financial lowered their target price on IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Barclays lowered their target price on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Monday, October 14th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.87.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.